Price
$1.24
Decreased by -0.17%
Dollar Volume
2.67 M
ADR%
14.73
Earnings Report Date (estimate)
Nov 7, 22 (N/A)
Market Cap.
25.81 M
Shares Float
6.29 M
Shares Outstanding
20.01 M
Beta
1.03
Price / Earnings
-1.04
BPR
34.15
20D Range
0.63 1.83
50D Range
0.61 1.83
200D Range
0.55 18.00
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 1.76 M
Increased by +384.17%
-7.82 M
Decreased by -574.23%
Decreased by -444.98%
Decreased by -39.26%
Jun 30, 22 636.63 K
Increased by +213.62%
-1.95 M
Decreased by -160.62%
Decreased by -306.94%
Increased by +16.90%
Mar 31, 22 87.20 K
Increased by +4.01 K%
-2.10 M
Decreased by -293.23%
Decreased by -2.41 K%
Increased by +90.44%
Dec 31, 21 26.40 K
Increased by +3.74 K%
-1.44 M
Decreased by -222.14%
Decreased by -5.47 K%
Increased by +91.62%
Sep 30, 21 363.05 K
Increased by +188.99 K%
-1.16 M
Decreased by -258.85%
Decreased by -319.54%
Increased by +99.81%
Jun 30, 21 202.99 K
Increased by +41.84 K%
-749.77 K
Decreased by -148.30%
Decreased by -369.36%
Increased by +99.41%
Mar 31, 21 2.12 K
Decreased by -86.05%
-534.01 K
Decreased by -41.69%
Decreased by -25.18 K%
Decreased by -915.42%
Dec 31, 20 687.00
Decreased by -69.64%
-448.49 K
Decreased by -21.18%
Decreased by -65.28 K%
Decreased by -299.16%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.